Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences

Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model... Purpose of reviewNonhuman primate (NHP) models of AIDS are powerful systems for evaluating HIV vaccine approaches in vivo. Authentic features of HIV-1 transmission, dissemination, target cell tropism, and pathogenesis, and aspects of anti-HIV-1 immune responses, can be recapitulated in NHPs provided the appropriate, specific model parameters are considered. Here, we discuss key model parameter options and their implications for HIV-1 vaccine evaluation.Recent findingsWith the availability of several different NHP host species/subspecies, different challenge viruses and challenge stock production methods, and various challenge routes and schemata, multiple NHP models of AIDS exist for HIV vaccine evaluation. The recent development of multiple new challenge viruses, including chimeric simian-human immunodeficiency viruses and simian immunodeficiency virus clones, improved characterization of challenge stocks and production methods, and increased insight into specific challenge parameters have resulted in an increase in the number of available models and a better understanding of the implications of specific study design choices.SummaryRecent progress and technical developments promise new insights into basic disease mechanisms and improved models for better preclinical evaluation of interventions to prevent HIV transmission. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and AIDS Wolters Kluwer Health

Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences

Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/nonhuman-primate-models-for-the-evaluation-of-hiv-1-preventive-vaccine-Ot8FjfBNmE

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000311
pmid
27559710
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewNonhuman primate (NHP) models of AIDS are powerful systems for evaluating HIV vaccine approaches in vivo. Authentic features of HIV-1 transmission, dissemination, target cell tropism, and pathogenesis, and aspects of anti-HIV-1 immune responses, can be recapitulated in NHPs provided the appropriate, specific model parameters are considered. Here, we discuss key model parameter options and their implications for HIV-1 vaccine evaluation.Recent findingsWith the availability of several different NHP host species/subspecies, different challenge viruses and challenge stock production methods, and various challenge routes and schemata, multiple NHP models of AIDS exist for HIV vaccine evaluation. The recent development of multiple new challenge viruses, including chimeric simian-human immunodeficiency viruses and simian immunodeficiency virus clones, improved characterization of challenge stocks and production methods, and increased insight into specific challenge parameters have resulted in an increase in the number of available models and a better understanding of the implications of specific study design choices.SummaryRecent progress and technical developments promise new insights into basic disease mechanisms and improved models for better preclinical evaluation of interventions to prevent HIV transmission.

Journal

Current Opinion in HIV and AIDS – Wolters Kluwer Health

Published: Nov 1, 2016

References

  • Derivation and characterization of pathogenic transmitted/founder molecular clones from SIVsmE660 and SIVmac251 following mucosal infection
  • Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env
  • Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes
  • Production of mucosally transmissible SHIV challenge stocks from HIV-1 circulating recombinant form 01_AE env sequences
  • Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
  • Nonhuman Primate HIV/SIV Vaccine Trials Database
  • Rhesus Genome Assembly: Nov. 2015 (BCM Mmul_8.0.1/rheMac8)
  • The UCSC Genome Browser database: 2016 update
  • Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention
  • Simian immunodeficiency virus infection evades vaccine-elicited antibody responses to V2 region
  • An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge
  • Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys
  • SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans
  • Depo-Provera does not alter disease progression in SIVmac-infected female Chinese rhesus macaques
  • Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque
  • Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses
  • Pathogenesis of SIVmac infection in Chinese and Indian rhesus macaques: effects of splenectomy on virus burden
  • Susceptibility of Chinese rhesus monkeys to SIV infection
  • Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses
  • A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey
  • Higher levels of IL-18 circulate during primary infection of monkeys with a pathogenic SHIV than with a nonpathogenic SHIV
  • Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys
  • Unusually high frequency MHC class I alleles in Mauritian origin cynomolgus macaques
  • Comprehensive characterization of MHC class II haplotypes in Mauritian cynomolgus macaques
  • T cell response specificity and magnitude against SIVmac239 are not concordant in major histocompatibility complex-matched animals
  • Expansion of simian immunodeficiency virus (SIV)-specific CD8 T cell lines from SIV-naive mauritian cynomolgus macaques for adoptive transfer
  • Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues
  • Characteristics of the menstrual cycle in nonhuman primates. IV. Timed mating in Macaca nemestrina
  • Combination emtricitabine and tenofovir disoproxil fumarate prevents vaginal simian/human immunodeficiency virus infection in macaques harboring Chlamydia trachomatis and Trichomonas vaginalis
  • Cataloguing of potential HIV susceptibility factors during the menstrual cycle of pig-tailed macaques by using a systems biology approach
  • The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge
  • Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques
  • Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen
  • Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model
  • SHIV susceptibility changes during the menstrual cycle of pigtail macaques
  • Short communication: practical experience with analysis and design of repeat low-dose SHIVSF162P3 exposure studies in female pigtail macaques with varying susceptibility during menstrual cycling
  • Relationship of estimated SHIV acquisition time points during the menstrual cycle and thinning of vaginal epithelial layers in pigtail macaques
  • Relationship of menstrual cycle and vaginal infection in female rhesus macaques challenged with repeated, low doses of SIVmac251
  • Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection
  • TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis
  • Evolution of a TRIM5-CypA splice isoform in old world monkeys
  • Independent evolution of an antiviral TRIMCyp in rhesus macaques
  • Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species
  • HIV-1-induced AIDS in monkeys
  • A variant macaque-tropic human immunodeficiency virus type 1 is resistant to alpha interferon-induced restriction in pig-tailed macaque CD4+ T cells
  • Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
  • Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV
  • Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock
  • Breakthrough virus neutralization resistance as a correlate of protection in a nonhuman primate heterologous simian immunodeficiency virus vaccine challenge study
  • Influence of mismatch of Env sequences on vaccine protection by live attenuated simian immunodeficiency virus
  • Monkeying around with HIV vaccines: using rhesus macaques to define ‘gatekeepers’ for clinical trials
  • Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys
  • Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus
  • Targeted isolation of antibodies directed against major sites of SIV Env vulnerability
  • TRIM5 allelic polymorphism in macaque species/populations of different geographic origins: its impact on SIV vaccine studies
  • TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species
  • The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge
  • The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys
  • Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys
  • Vaccination against endogenous retrotransposable element consensus sequences does not protect rhesus macaques from SIVsmE660 infection and replication
  • In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein
  • Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques
  • Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
  • AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
  • A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges
  • Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques
  • Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus
  • Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques
  • Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose
  • Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge
  • Oral immunization with recombinant vaccinia virus prime and intramuscular protein boost provides protection against intrarectal simian-human immunodeficiency virus challenge in macaques
  • Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins
  • Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer
  • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a nonpoisson distribution of transmitted variants
  • Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
  • High multiplicity infection by HIV-1 in men who have sex with men
  • Human nonneutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques
  • Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
  • Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure
  • Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys
  • Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1
  • SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma
  • Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies
  • HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity
  • The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant
  • The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity
  • Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay
  • Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events
  • Nonhuman primate models for cell-associated simian immunodeficiency virus transmission: the need to better understand the complexity of HIV mucosal transmission
  • Tracking the luminal exposure and lymphatic drainage pathways of intravaginal and intrarectal inocula used in nonhuman primate models of HIV transmission
  • A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251
  • Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine
  • Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
  • A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge
  • Progesterone implants enhance SIV vaginal transmission and early virus load
  • High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques
  • Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys